Company intelligence / Profile preview
EG 427
Paris, Ile de France, Franceeg427.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
EG 427 has initiated a first-in-human clinical study with its lead gene therapy candidate, EG110A, targeting neurogenic detrusor overactivity. The company’s proprietary HERMES platform uses non-replicative HSV‑1 vectors to deliver durable and selective transgene expression to neural cells. Early preclinical data have shown positive safety and efficacy signals; the ongoing Phase 1b/2a trial will provide initial human safety data by mid‑2025. The company aims to address significant unmet needs in neuro-urology with potential expansion into broader neurological diseases.
- Therapeutic areas
- Women's HealthNeurologyUrology
- Modalities
- Gene therapy (non-replicative HSV-1 vector)DNA medicines
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
No major pharma partnerships disclosed as of May 2025; key investors include Andera Partners, Bpifrance/InnoBio funds, SCI Ventures
Beyond the preview
Go deeper on EG 427.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EG 427.